The IL-6Rα (and Signal transducers and activators of transcription 3 (STAT3) oncogenic pathway) expression in aggressive, castration-resistant prostate cancer has recently been assessed in patients, making this receptor and pathway of high interest for targeting therapeutic interventions [13]. The gene discussed is STAT3; the disease is prostate carcinoma.